Cargando…

EMMY: The continued expansion of clinical applications of SGLT2 inhibitors

Introduction: Myocardial infarction (MI) is a challenging clinical and public health problem and is a leading cause of morbidity and mortality worldwide. Heart failure (HF) is a common sequela of acute myocardial infarction (AMI), with an incidence of up to 40% among hospitalized patients and has im...

Descripción completa

Detalles Bibliográficos
Autor principal: Kotit, Susy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Magdi Yacoub Heart Foundation 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988294/
https://www.ncbi.nlm.nih.gov/pubmed/36890845
http://dx.doi.org/10.21542/gcsp.2023.5
_version_ 1784901546668982272
author Kotit, Susy
author_facet Kotit, Susy
author_sort Kotit, Susy
collection PubMed
description Introduction: Myocardial infarction (MI) is a challenging clinical and public health problem and is a leading cause of morbidity and mortality worldwide. Heart failure (HF) is a common sequela of acute myocardial infarction (AMI), with an incidence of up to 40% among hospitalized patients and has important implications for treatment and prognosis. Sodium–glucose co-transporter 2 inhibitors (SGLT2i), such as empagliflozin, have been shown to reduce the risk of hospitalization and cardiovascular mortality in patients with symptomatic HF and have therefore been included in the European and American heart failure guidelines. However, trials investigating the effects of this drug class in patients following acute myocardial infarction are lacking. Study and Results: The EMMY trial was conducted to assess the safety and efficacy of empagliflozin in patients with acute myocardial infarction (AMI). A total of 476 patients with AMI were randomly assigned to empagliflozin (10 mg) or matching placebo once daily within 72 h of percutaneous coronary intervention. The primary outcome was the N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP) change over 26 weeks. Secondary outcomes included changes in echocardiographic parameters. NT-proBNP reduction was significantly greater in the empagliflozin group (−15% after adjusting for baseline NT-proBNP, gender, and diabetes status (P = 0.026)). Absolute left-ventricular ejection fraction improvement was 1.5% (P = 0.029) greater, mean E/e′ reduction was 6.8% (P = 0.015) greater, and left-ventricular end-systolic and end-diastolic volumes were lower by 7.5 mL (P = 0.0003) and 9.7 mL (P = 0.0015), respectively, in the empagliflozin group, compared with placebo. Seven patients were hospitalized for HF (3 in the empagliflozin group). Other predefined serious adverse events were rare and did not differ significantly between groups. Lessons learned: The EMMY trial shows that early use of the SGLT2 inhibitor empagliflozin after acute myocardial infarction (MI) improves natriuretic peptide levels and markers of cardiac function and structure supporting the use of Empagliflozin in HF related to a recent MI.
format Online
Article
Text
id pubmed-9988294
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Magdi Yacoub Heart Foundation
record_format MEDLINE/PubMed
spelling pubmed-99882942023-03-07 EMMY: The continued expansion of clinical applications of SGLT2 inhibitors Kotit, Susy Glob Cardiol Sci Pract Lessons from the Trials Introduction: Myocardial infarction (MI) is a challenging clinical and public health problem and is a leading cause of morbidity and mortality worldwide. Heart failure (HF) is a common sequela of acute myocardial infarction (AMI), with an incidence of up to 40% among hospitalized patients and has important implications for treatment and prognosis. Sodium–glucose co-transporter 2 inhibitors (SGLT2i), such as empagliflozin, have been shown to reduce the risk of hospitalization and cardiovascular mortality in patients with symptomatic HF and have therefore been included in the European and American heart failure guidelines. However, trials investigating the effects of this drug class in patients following acute myocardial infarction are lacking. Study and Results: The EMMY trial was conducted to assess the safety and efficacy of empagliflozin in patients with acute myocardial infarction (AMI). A total of 476 patients with AMI were randomly assigned to empagliflozin (10 mg) or matching placebo once daily within 72 h of percutaneous coronary intervention. The primary outcome was the N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP) change over 26 weeks. Secondary outcomes included changes in echocardiographic parameters. NT-proBNP reduction was significantly greater in the empagliflozin group (−15% after adjusting for baseline NT-proBNP, gender, and diabetes status (P = 0.026)). Absolute left-ventricular ejection fraction improvement was 1.5% (P = 0.029) greater, mean E/e′ reduction was 6.8% (P = 0.015) greater, and left-ventricular end-systolic and end-diastolic volumes were lower by 7.5 mL (P = 0.0003) and 9.7 mL (P = 0.0015), respectively, in the empagliflozin group, compared with placebo. Seven patients were hospitalized for HF (3 in the empagliflozin group). Other predefined serious adverse events were rare and did not differ significantly between groups. Lessons learned: The EMMY trial shows that early use of the SGLT2 inhibitor empagliflozin after acute myocardial infarction (MI) improves natriuretic peptide levels and markers of cardiac function and structure supporting the use of Empagliflozin in HF related to a recent MI. Magdi Yacoub Heart Foundation 2023-01-30 /pmc/articles/PMC9988294/ /pubmed/36890845 http://dx.doi.org/10.21542/gcsp.2023.5 Text en Copyright ©2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Lessons from the Trials
Kotit, Susy
EMMY: The continued expansion of clinical applications of SGLT2 inhibitors
title EMMY: The continued expansion of clinical applications of SGLT2 inhibitors
title_full EMMY: The continued expansion of clinical applications of SGLT2 inhibitors
title_fullStr EMMY: The continued expansion of clinical applications of SGLT2 inhibitors
title_full_unstemmed EMMY: The continued expansion of clinical applications of SGLT2 inhibitors
title_short EMMY: The continued expansion of clinical applications of SGLT2 inhibitors
title_sort emmy: the continued expansion of clinical applications of sglt2 inhibitors
topic Lessons from the Trials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988294/
https://www.ncbi.nlm.nih.gov/pubmed/36890845
http://dx.doi.org/10.21542/gcsp.2023.5
work_keys_str_mv AT kotitsusy emmythecontinuedexpansionofclinicalapplicationsofsglt2inhibitors